dabrafenib 75 MG Oral Capsule [Tafinlar]

Known as: DABRAFENIB MESYLATE 75 mg ORAL CAPSULE [Tafinlar], Tafinlar 75 MG (as dabrafenib mesylate 88.88 MG) Oral Capsule, Tafinlar 75 MG Oral Capsule 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The BRAF inhibitor dabrafenib (Tafinlar®) and the MEK inhibitor trametinib (Mekinist®) are indicated, as monotherapy or in… (More)
  • table 1
  • figure 1
Is this relevant?
2015
2015
Trametinib (Mekinist®) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) approved in the United States as… (More)
Is this relevant?
2013
2013
Dabrafenib (Tafinlar®), a mutant-BRAF kinase inhibitor, emerged from GlaxoSmithKline’s research programme for the discovery of… (More)
Is this relevant?
2013
2013
Mutations of the BRAF gene are present in about 50% of all melanomas and 80-90% of these BRAF-positive melanomas show a V600E… (More)
Is this relevant?